Continuous increase of bacterial resistance to antibiotics causes many problems such as the advent of resistance to pathogenic bacteria, difficulty of microbial disease treatments, environmental pollution and others. It is inevitable to find potential substitutes for antibiotics in order to solve the above mentioned problems. Recently many literatures have shown that probiotics could be applied to the treatment or amelioration of respiratory diseases in addition to intensively studied gut related diseases. Target diseases for collecting data and analysis of the efficacies were chosen because viral respiratory infections are the most common diseases in humans. They were mainly viral diseases like common colds, pneumonia in addition to allergies and asthma. Papers on clinical efficacies, safety risks and mechanisms of microbial action of respiratory diseases were secured through known information sites and analyzed for their exact evaluations. The present analysis of research results on probiotics efficacies for respiratory diseases showed discrepancies in efficacies. On the whole, half to one third of papers reviewed only showed certain level of efficacies against respiratory viral diseases. It is very difficult to compare the results directly because the studies varied highly in study design, outcome measures, probiotics, dose, and matrices used. However, the results obtained so far show the potential applications of probiotics to the prevention or amelioration of the diseases. Conclusively, further well organized studies using randomized, double-blind, placebo-controlled clinical trials are needed to elucidate the realities of probiotics on respiratory related diseases and to obtain more definite efficacy results.
INTRODUCTION
Therefore, the present articles reviewed related reference published on clinical trials, and described the mechanisms of action and safety of probiotics used for the respiratory tract diseases. Probiotics are known to be different in efficacies and other properties depending on strains developed for products even though within same species. This specific properties of probiotics require caution in reading of related study results.
Probiotics and respiratory tract
Respiratory tract has specific properties of microbiota other than those of intestinal tract. Therefore, in order to understand probiotics acting on respiratory tract diseases, composition of microbiota in respiratory tract and related functions should be investigated. Research papers on the microbiota in respiratory tract and potential use of probiotics for the related diseases were reviewed and analyzed in the followings.
1-1) Microbial constituents and diseases in respiratory tract
There are possibilities that microbiota which is distinct in constitution in human body tract interacts each other and its host regardless of not enough evidence in vivo (11, 12) .
Even though most researches on microbiota in human body had been performed from human intestinal tracts, those on respiratory tract microbiota are being elucidated and advanced owing to modern biotechnologies (13) . Even today, it is difficult to secure evidence that respiratory microbiota constituents and functions are similar in developing and maintaining immune activities of the lung to intestinal microbiota. Nonetheless, there is increasing evidences that relationships between the respiratory microbiota and many lung diseases are shown and microbial changes in respiratory microbiota could cause diseases in human (Fig. 1) . Furthermore, studies on the possible existence of "core respiratory tract microbiota" are suggested. It is known that microbiota of respiratory tract are mainly composed of Pseudomonas, Streptococcus, and many other bacteria. The "core respiratory microbiota" might be distinct depending on factors such as ethnic groups, environments like diets and many others.
The presence of core respiratory microbiota and changes in its constituents dependent on individual health conditions It was reported that respiratory tracts including alveoli and bronchioles of healthy persons demonstrated the presence of bacteria by using more sensitive molecular methods including PCR (14) . Microbial constituents of the above tracts were the same as those found in the upper respiratory tracts, whereas the bacterial concentration in lung is in much fewer levels. It is suggested that bacteria in alveolar could come from the upper respiratory tracts when considering similar bacterial constituents in alveolar and lung (15) . It was also reported that the pulmonary microbiota in patients showing pneumonia (16) and bronchitis (17) was complex in microbial compositions. Owing to understanding of predominant bacteria in human respiratory tracts in healthy persons and patients, it was possible to understand the changes induced in a particular microbiota when using pro- Other factors include various endpoint, populations employed, genetics and environments.
1-3) Efficacy of probiotics against viral infections
Many researchers performed studies on the efficacies of probiotics against viral diseases (28~30). One study on rhinovirus infection using reported results on 94 infants who were treated at a hospital allocated to receive oral prebiotics or probiotics on days of 3 and 60 (29) . The main parameters of the study were the incidence of virusassociated respiratory tract infection episodes and the severity and duration of viral respiratory infections. A significantly lower incidences of respiratory infections were detected in infants receiving probiotics, contrary to control groups.
Furthermore, rhinovirus-induced incidences in the probiotic administered groups were lower, compared with the controls.
No differences in rhinovirus RNA load during infections or occurrence of rhinovirus RNA in asymptomatic infants were shown in the study groups. The study concluded that microbiota modification with specific prebiotics and probiotics might be a means for reducing rhinovirus infections (30) . Antibiotics are mostly used for the treatments of common viral respiratory diseases which are usually caused by common cold and influenza (31) . For these reasons, future main targets of probiotics uses could be for respiratory diseases following gastrointestinal diseases (32) . 
1-4) Probiotics for pneumonia
Pneumonia is an inflammatory condition of the lung affecting mainly air sacs called alveoli and mostly caused by infection with microorganisms including viruses and bacteria.
Recently one approach for pneumonia is the introduction of probiotics at the oro-pharyngeal level or by nasal oro- In the study on the efficacy of probiotics on pneumonia, the primary endpoint was the delay before isolation of P.
aeruginosa in gastric and respiratory samples, whether causing colonization or infection (43) . The delay before acquisition of this bacterium was significantly different between the two groups; the delay in the control group was 11 days on average while it was 50 days in the probiotic administered group. The two groups did not show any differences in the incidence of P. aeruginosa pneumonia Table 1 .
1-5) Probiotics on allergy
Researches on patients with allergy efficacies by pro- Conclusively, probiotics effects on allergies and/or have not been conclusive and could be different by target subjects, strains used, and authors performing the studies.
Mechanisms of probiotics action in respiratory tract
Exact mechanisms of probiotics action on respiratory tracts are still unclear. Furthermore, the mechanisms of probiotics seem different depending on probiotics species and specific strains. There seem to be multiple mechanisms in probiotic activity depending on probiotics characteristics and target diseases. Multiple microbe-microbe and microbehost interactions probably account for the versatility of probiotic action. However, it seems likely that probiotics have similar effects on the whole. The same mechanisms of anti-inflammatory actions as gut system might be applied to respiratory tract very possibly.
2-1) Direct antimicrobial activity by probiotics
So far, evidence on probiotics has been mostly secured Lactococcus lactis strain could deliver the anti-inflammatory cytokines or enzymes to the gastro-intestinal organs. However, the introduction of genetically modified probiotics in human require no risk to public health and technology of controlling and eliminating the modified organism if necessary.
2-2) Probiotics action on epithelium barrier function
In [15] . In order to demonstrate the protective effects by probiotics on respiratory tract, the development of well organized and randomized double blind clinical trials is considered mandatory.
As another example of clinical study, West et al. (27) examined cell-mediated immune mechanisms following daily supplementation with Bifidobacterium animalis subsp. Nevertheless, researchers even majoring on probiotics have not reported any such adverse effects (22) . However, it should be kept in mind that even probiotics is a living organism and opportunistic infection could occur theoretically, even though probiotics including the Lactobacillus genus are tested to be some of the safest micro-organisms.
Therefore, safety of all the probiotics strains should be demonstrated completely before use since each specifically interacts with the host. In addition, all the properties of bacteria used as probiotics at the infra-specific level should be identified completely for making sure they are safe for the target patients.
Requirements for the development as probiotics
In order to be used as probiotics for human, several criteria should be satisfied with properties necessary for safety and function mainly. First of all, the safety of pro- 
CONCLUDING REMARKS
In this review, many literatures on the clinical trials using probiotics were collected and analyzed, depending on health benefit and infection control. However, for the uses of the airway microbiota in respiratory therapy, the more detailed mechanisms of microbiota functions should be elucidated. Presently it is interpreted that differences in strains, hosts and study performances might cause split results of efficacies. However, considering all these results obtained so far, it is considered that probiotics might have the potentials of preventions for respiratory diseases. In addition, for the human uses of probiotics, safety problems should be considered with special emphasis on compromised persons. Conclusively there are possibilities that probiotics could be used in the areas of allergies, asthma or wheezing in addition to various respiratory diseases when many technical problems concerned are solved.
